. "Appendix C: Observers at the Workshop on Antiprogestins." Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda. Washington, DC: The National Academies Press, 1993.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
Seymour Romney, M.D.
Albert Einstein School of Medicine
Sarah Samuels, Dr.P.H.
Henry J. Kaiser Family Foundation
Professor Gilbert Schiason
Hopital de Bicêtre Paris, France
Ekkehard Schillinger, M.D.
Schering AG Berlin, Germany
Sheldon Segal, Ph.D.
Population Council New York, New York
Solomon Sobel, M.D.
Food and Drug Administration
Jeff Spieler
Agency for International Development Washington, D.C.
Catherine Stika, M.D.
Northwestern University
Irene Stith-Coleman, Ph.D.
Congressional Research Service Washington, D.C.
Pamela Stratton, M.D.
National Institute of Child Health and Human Development
National Institutes of Health
Rosemarie Thau, Ph.D.
Population Council New York, New York
Helena von Hertzen, D.D.S., M.D.
World Health Organization Geneva, Switzerland
Charles Watlington, M.D., Ph.D.
Virginia Commonwealth University
Beverly Winikoff, M.D., M.P.H.
Population Council New York, New York
Susan Wood, Ph.D.
Congressional Caucus for Women's Issues Washington, D.C.
IOM STAFF
Kenneth Shine, M.D.
President
Enriqueta Bond, Ph.D.
Executive Officer
Michael Stoto, Ph.D.
Director, Division of Health Promotion and Disease Prevention
Ruth Bulger, Ph.D.
Director, Division of Health Sciences Policy
Molla Donaldson, M.S.
Study Director
Sarah Brown, M.P.H.
Senior Program Officer
Karen Foote
Commission on Behavioral and Social Sciences and Education (National Research Council)